We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Wireless CranioFacial Nerve Stimulation (CFNS) for the Treatment of CranioFacial Neuropathic Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02729480
Recruitment Status : Recruiting
First Posted : April 6, 2016
Last Update Posted : December 14, 2017
Sponsor:
Collaborators:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to assess the effectiveness of craniofacial nerve stimulation for the treatment of neuropathic pain.

Condition or disease Intervention/treatment
Facial Pain Device: Halo Craniofacial Nerve Stimulator System

Detailed Description:

Subjects will be randomized at enrollment into either a delayed or immediate continuation group. The immediate continuation group will immediately continue with the stimulation after a 30-day trial period and will be monitored for a total of 12 months. The delayed activation group will have their device turned off after the 30-day trial period for the next 3-months. At the 3-month visit, both groups be evaluated and the delayed activation group will have their devices reactivated.

Subjects will have neuropathic pain of various etiologies, including trauma, surgery or post-herpetic infections. Stimulators will be placed at the site target of the painful area, including the epifascial plane under the skin but above the muscles in the vicinity of the targeted branches of; A. Branches of Trigeminal Nerves in the Ophthalmic, Maxillary, or Mandibular B. Sensory branches of Facial Nerves C. Branches of the Occipital Nerves (Greater and/or Lesser) D. Branches of the Cervical Plexus (Superficial and/or Deep)


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multi-center, Prospective, Controlled, Clinical Trial of Wireless CranioFacial Nerve Stimulation (CFNS) for the Treatment of CranioFacial Neuropathic Pain
Actual Study Start Date : February 1, 2017
Estimated Primary Completion Date : February 2018
Estimated Study Completion Date : November 2018
Arms and Interventions

Arm Intervention/treatment
Experimental: Continued Stimulation Group
Subjects randomized to this group will have the Halo Craniofacial Nerve Stimulator System activated immediately.
Device: Halo Craniofacial Nerve Stimulator System
The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
Active Comparator: Delayed Continuation Group
Subjects randomized to this group with have the Halo Craniofacial Nerve Stimulator System activated after 90 days.
Device: Halo Craniofacial Nerve Stimulator System
The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.


Outcome Measures

Primary Outcome Measures :
  1. Pain Score [ Time Frame: 3 months ]
    To achieve a sustained 50% reduction in pain measured by the Visual Analog Scale (VAS)

  2. Incidence and severity of adverse events [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Percentage change from baseline in VAS for facial pain [ Time Frame: Baseline and 3 months ]
  2. Percent change from baseline in the Brief Pain Inventory-facial (BPIF) Questionnaire [ Time Frame: Baseline and 3 months ]
  3. Subject satisfaction with the therapy as measured by the Patient Global Impression of Change (PGIC) [ Time Frame: 3 months ]
  4. Change from baseline in quality of life, Physical component score using Medical Outcomes Short Form SF-36 [ Time Frame: Baseline and 3 months ]
  5. Change from baseline in quality of life, Mental component score using Medical Outcomes Short Form SF-36 [ Time Frame: Baseline and 3 months ]
  6. Change from baseline in pain rating index from the Short Form McGill Pain Questionnaire (MPQ-SF-2) [ Time Frame: Baseline and 3 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is ≥ 18 years of age at time of informed consent
  • Subjects have been diagnosed with Cranial-facial pain with an average VAS > 5 (on a 0-10 scale) over the course of the last month based on baseline pain diary.
  • Subject diagnosis with neuropathic cranial-facial pain refractory to conventional medical management for at least 12 months prior to enrollment;
  • Based on the medical opinion of the Principal Investigator, subject has a stable pain medication regimen for 3 months prior to study entry.
  • Based on the medical opinion of the Principal Investigator, subject has a stable Tricyclic regimen for 3 months prior to study entry
  • No medication overuse and not attributed to another causative disorder
  • Based on the medical opinion of the Principal Investigator, there is no evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject;
  • Based on the opinion of the Principal Investigator, subject is willing and able to operate the patient programmer, recharging equipment, diary and has the ability to undergo study assessments and provide accurate responses;
  • Based on the opinion of the implanter, subject is a good surgical subject for the implant procedure;
  • Subject is willing to undergo surgical implant procedure, attend visits as scheduled, and comply with the study requirements;
  • Subject is male or non-pregnant female as determined with a negative pregnancy test at baseline visit, and if sexually active, must be using a medically acceptable method of contraception for the duration of their study participation;
  • Subject is deemed to be neuro-psycho-socially appropriate for implantation therapies based of the assessment of a Clinical Psychologist, using face-to-face encounters and the psychological testing described in the measures;
  • Patient is capable of giving informed consent

Exclusion Criteria:

  • A. Subject has undergone botulinum toxin (BOTOX) injections of the head and/or neck in the last 3 months.
  • Unresolved Malignancies in last six months;
  • Subject has a history of migraine, headaches of central origin or trigeminal autonomic cephalalgias;
  • Subject has postherpetic neuralgia (shingles);
  • Complete deafferentation of all branches of the trigeminal, facial, occipital nerves and cervical plexus;
  • Subject has an active systemic infection or is immune-compromised;
  • Based on the medical opinion of the Principal Investigator, Psychologist and/or Psychiatrist, the subject has other psychological conditions (e.g., psychosis, suicidal ideation, borderline personality disorder, somatization, narcissism), other health conditions (e.g., substance abuse, another chronic condition requiring the regular use of opioid medication), or other legal concerns that would preclude his/her enrollment in the study or potentially confound the results of the study;
  • Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device study while participating in this study;
  • Insulin-dependent diabetic who is not controlled through diet and/or medication (determined by the physician) or non-insulin dependent diabetic who is not well controlled through diet and/or medication;
  • Bleeding complications or coagulopathy issues;
  • Pregnant/lactating or not using adequate birth control;
  • A life expectancy of less than one year;
  • Any active implanted device whether turned off or on;
  • A previous peripheral nerve stimulator (PNS) experience for the treatment of facial pain including a failed trial or explanted device;
  • Conditions requiring Magnetic Resonance Imaging (MRI) evaluation or diathermy procedures;
  • Subject is currently involved in litigation regarding injury, or is receiving worker's compensation benefits.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02729480


Contacts
Contact: Niek Vanquathem 0032 492 69 22 23 niek@freedomneuro.com

Locations
United States, District of Columbia
International Spine, Pain & Performance Center Recruiting
Washington, District of Columbia, United States, 20037
Contact: Juline Panneerselvam    202-808-8295    schedule@isppcenter.com   
Principal Investigator: Mehul Desai         
United States, Indiana
Goodman Campbell Brain and Spine, Indiana University Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Jennifer Pencek    317-396-1286    jpencek@goodmancampbell.com   
Principal Investigator: Albert LEE, MD         
United States, Michigan
Prizm Pain Management Recruiting
Canton, Michigan, United States, 48187
Contact: Sikar Grewal    248-564-1485    sikar_grewal@yahoo.com   
Principal Investigator: Jeffrey Rosenberg, MD         
United States, New York
Minimally Invasive Pain Institute Recruiting
Utica, New York, United States, 13502
Contact: Mary Sullivan    315-798-8737 ext 215    Mary.Sullivan@killpain.com   
Principal Investigator: Nameer Haider         
United States, Ohio
University Hospitals Case Medical Center, Department of Anesthesiology, Division of Pain Medicine Recruiting
Cleveland, Ohio, United States, 44106
Contact: Carmen Czich    216-983-5124    Carmen.Czich@UHhospitals.org   
Principal Investigator: Salim Hayek, MD         
United States, Pennsylvania
Pennsylvania Hospital, Dept. of Neurosurgery Recruiting
Philadelphia, Pennsylvania, United States, 19106
Contact: Marie Kerr    215-829-6720    kerrm@uphs.upenn.edu   
Principal Investigator: John Y Lee, MD         
United States, Texas
baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Melyssa Fink    713-798-1037    Melyssa.Fink@bcm.edu   
Principal Investigator: Ashwin Viswanathan, MD         
Sponsors and Collaborators
StimRelieve, LLC
Goodman Campbell Brain and Spine, Indiana University, Indianapolis, Indiana, USA
International Spine, Pain and Performance Center, Washington DC, USA
Minimally Invasive Pain Institute, Utica, New York, USA
Case Western Reserve University, Cleveland, Ohio, USA
Pennsylvania Hospital, Philadelphia, Pennsylvania, USA
Baylor College of Medicine, Houston, USA
Prizm Pain Management, Canton, Michigan
More Information

Responsible Party: StimRelieve, LLC
ClinicalTrials.gov Identifier: NCT02729480     History of Changes
Other Study ID Numbers: 30-00208
First Posted: April 6, 2016    Key Record Dates
Last Update Posted: December 14, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified participant data for all primary endpoints will be made available within 6 months of study completion.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No

Additional relevant MeSH terms:
Neuralgia
Facial Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms